LERADO FIN(01225)
Search documents
隆成金融(01225) - 2023 - 年度业绩
2024-03-28 14:51
Financial Performance - Total revenue for the year ended December 31, 2023, was HKD 191,422,000, a decrease of 12.26% from HKD 218,238,000 in 2022[2] - The company reported a net loss of HKD 279,395,000 for the year, an improvement of 24.0% compared to a net loss of HKD 367,637,000 in 2022[3] - Basic and diluted loss per share was HKD 121.34 cents, compared to HKD 159.37 cents in the previous year, indicating a reduction in loss per share[3] - The group reported a consolidated loss before tax of HKD 278,243,000 for the year ended December 31, 2023, compared to a loss of HKD 345,563,000 in 2022[19] - The loss for the year was approximately HKD 279.4 million, compared to HKD 367.6 million in 2022, primarily due to impairment losses on receivables of about HKD 285.4 million[61] Revenue Breakdown - The group's revenue for medical products decreased to HKD 71,956,000 in 2023 from HKD 85,528,000 in 2022, representing a decline of approximately 16%[16] - Revenue from medical products for the year ended December 31, 2023, was approximately HKD 72,000,000, a decrease of about 15.9% compared to the previous year, primarily due to overall economic downturn[43] - Revenue from plastic toys decreased by approximately 2.6% to about HKD 7,200,000, mainly due to intense market competition[43] - Revenue from external customers in Hong Kong decreased to HKD 112,244,000 in 2023 from HKD 125,295,000 in 2022, a decline of approximately 10.4%[23] - The external revenue from the securities brokerage and asset management services segment was HKD 3,288,000 in 2023, down from HKD 2,074,000 in 2022[19] Assets and Liabilities - Total assets decreased to HKD 1,184,103,000 from HKD 1,484,341,000, reflecting a decline of 20.2% year-over-year[5] - The company's total equity decreased to HKD 428,359,000 from HKD 680,759,000, a decline of 37.0% year-over-year[5] - The net current assets as of December 31, 2023, were approximately HKD 1,121.8 million, down from HKD 1,397.1 million in 2022, with a current ratio of about 6.8[63] - The debt-to-equity ratio increased to approximately 172.8% as of December 31, 2023, compared to 116.0% in 2022[63] Cash Flow and Financial Management - The company's cash and cash equivalents decreased to HKD 127,822,000 from HKD 175,020,000, a decline of 27.0%[5] - The company incurred financial expenses of HKD 52,313,000, down 25.8% from HKD 70,448,000 in the previous year[2] - Interest income from loans was HKD 108,954,000 in 2023, compared to HKD 122,093,000 in 2022, reflecting a decline of approximately 10.5%[16] - The company recorded a fair value loss of approximately HKD 13,328,000 on financial assets measured at fair value through profit or loss for the year ended December 31, 2023, compared to a gain of HKD 51,600,000 in 2022[39] Impairment and Credit Risk - The company recognized a net impairment loss of HKD 292,066,000, a decrease of 8.2% from HKD 318,160,000 in 2022[2] - As of December 31, 2023, the company had 169 impaired loans, with no significant impairments leading to legal action for overdue loans[49] - The company expects credit losses to be primarily based on three key indicators: default risk, default rate, and default loss, with the total accounts receivable value as of December 31, 2023, being the basis for these estimates[48] - The company emphasizes the importance of managing credit risk through regular reviews and monitoring of loan repayment situations, including discussions with borrowers regarding repayment terms[52] Corporate Governance - The company has complied with the corporate governance code as per the listing rules throughout the year ending December 31, 2023[78] - The audit committee, consisting of three independent non-executive directors, reviewed the accounting principles and financial reporting matters for the year ending December 31, 2023[79] - The company has adopted the standard code and confirmed full compliance with its provisions for the entire year ending December 31, 2023[80] - The financial statements for the year ending December 31, 2023, have been audited and are consistent with the preliminary figures disclosed[82] Future Plans and Strategy - The group plans to continue focusing on its core segments, including medical products and financial services, while exploring potential market expansions and new product developments[21] - The company plans to focus on expanding its financial services in Hong Kong and China, including lending, leasing, and securities brokerage[60] - The company has initiated the development of asset management services and plans to launch various funds to attract new investors, although no revenue was generated from this segment in the current year due to weak market conditions[44] Dividend Policy - The company does not recommend the distribution of a final dividend for the year ended December 31, 2023, consistent with the previous year[33] - The board did not recommend the payment of a final dividend for the year ended December 31, 2023[70]
隆成金融(01225) - 2023 - 中期财报
2023-09-29 08:35
Revenue Performance - Revenue for the six months ended June 30, 2023, was HKD 79,802,000, a decrease of 4.9% compared to HKD 83,210,000 in the same period of 2022[4] - Revenue from medical products for the six months ended June 30, 2023, was HKD 35,447,000, down from HKD 42,892,000 in the same period of 2022, representing a decline of approximately 17.3%[26] - Revenue from plastic toys decreased to HKD 1,852,000 from HKD 2,708,000, a decline of about 31.6% year-over-year[26] - The total revenue for the group for the six months ended June 30, 2023, was HKD 79,802,000, compared to HKD 83,210,000 in the same period of 2022, indicating a decrease of about 4.9%[26] - For the six months ended June 30, 2023, the total revenue was approximately HKD 79,800,000, a decrease of about 4.1% compared to HKD 83,200,000 for the same period in 2022[70] - Revenue from medical products was approximately HKD 35,400,000, a decrease of about 17.4% year-on-year[63] - Revenue from plastic toys decreased by approximately 31.6% to about HKD 1,900,000, primarily due to a reduction in orders from Chinese customers[63] Profit and Loss - The company reported a loss before tax of HKD 19,247,000, significantly improved from a loss of HKD 99,860,000 in the previous year[4] - Total comprehensive loss for the period was HKD 15,607,000, compared to a loss of HKD 106,762,000 in the same period last year, indicating a substantial reduction in losses[6] - Basic and diluted loss per share improved to HKD 8.83 from HKD 43.74 year-over-year[8] - The group reported a pre-tax loss of HKD 20,274,000 for the six months ended June 30, 2023, compared to a pre-tax loss of HKD 101,145,000 in the same period of 2022, showing an improvement in loss by approximately 80%[28] - The company reported a loss attributable to owners of approximately HKD 20,338,000 for the six months ended June 30, 2023, compared to a loss of HKD 100,751,000 for the same period in 2022, indicating a significant improvement[42] - The company reported a loss of approximately HKD 19,300,000 for the six months ended June 30, 2023, compared to a loss of HKD 101,100,000 in the same period of 2022[70] Assets and Liabilities - Non-current assets totaled HKD 85,484,000 as of June 30, 2023, slightly down from HKD 87,204,000 at the end of 2022[10] - Current assets increased to HKD 1,619,292,000 from HKD 1,595,449,000, driven by an increase in trade and other receivables[10] - Current liabilities rose to HKD 248,043,000 from HKD 198,312,000, reflecting an increase in trade and other payables[12] - Total equity decreased to HKD 665,152,000 from HKD 680,759,000, primarily due to the losses incurred during the period[12] - The total amount of trade and other receivables and prepayments increased to HKD 118,149,000 as of June 30, 2023, up from HKD 106,550,000 as of December 31, 2022, reflecting a growth of approximately 10.5%[44] - The total receivables from loans amounted to HKD 1,230,826,000 as of June 30, 2023, compared to HKD 1,200,710,000 as of December 31, 2022, representing an increase of approximately 2.5%[48] - The company's total liabilities included bonds payable of approximately HKD 777,700,000, a slight decrease from HKD 789,800,000 as of December 31, 2022[71] Cash Flow - The net cash generated from operating activities for the six months ended June 30, 2023, was HKD 18,569,000, a significant increase from HKD 3,816,000 in the same period of 2022, representing a growth of approximately 387%[15] - The net cash used in investing activities was HKD (14,781,000), compared to HKD (8,576,000) in the previous year, indicating an increase in investment outflows of approximately 72.5%[15] - The net cash used in financing activities was HKD (12,427,000), a decrease from HKD 6,662,000 in the prior year, reflecting a change of approximately 286%[15] - The total cash and cash equivalents as of June 30, 2023, amounted to HKD 171,140,000, up from HKD 157,303,000 at the end of June 2022, marking an increase of about 8.5%[15] - As of June 30, 2023, the company's cash and cash equivalents decreased by approximately HKD 3,900,000 to about HKD 171,100,000[71] Financial Ratios and Performance Metrics - The gross profit margin for the six months ended June 30, 2023, was approximately 62.3%, an increase of about 5.6% from 56.7% in the same period of 2022[70] - The current ratio as of June 30, 2023, was approximately 6.5, down from 8.0 as of December 31, 2022[71] Corporate Governance and Compliance - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2023, consistent with the previous year[39] - The board did not recommend an interim dividend for the six months ended June 30, 2023, similar to the previous year[80] - The company has complied with the corporate governance code throughout the reporting period[91] - The audit committee reviewed the accounting principles and financial reporting matters for the six months ended June 30, 2023[92] Risk Factors - The group has no foreign exchange hedging policies in place, exposing it to risks from currency fluctuations, particularly with the Chinese Yuan[75] - The group faces stock price risk due to investments in listed securities, with no hedging policies currently established[76] - As of June 30, 2023, there were no significant contingent liabilities reported[77] Employment and Operations - The group employed a total of 210 employees as of June 30, 2023, with 180 based in China[79] - As of June 30, 2023, there were no purchases, sales, or redemptions of the company's listed securities during the six months ended June 30, 2023[81] - As of June 30, 2023, there were no unexercised options under the 2022 share option scheme[83] - The company plans to focus on expanding its financial services, including corporate financing and asset management, despite challenges posed by the COVID-19 pandemic[67]
隆成金融(01225) - 2023 - 中期业绩
2023-08-31 14:57
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Lerado Financial Group Company Limited 隆 成 金 融 集 團 有 限 公 司 (於百慕達註冊成立之有限公司) (股份代號:1225) 截至二零二三年六月三十日止六個月之中期業績公佈 隆成金融集團有限公司(「本公司」)董事(「董事」)會(「董事會」)呈列本公司及其 附屬公司(統稱「本集團」)截至二零二三年六月三十日止六個月之未經審核綜合 業績連同比較數字及經選擇說明附註,此乃根據香港會計師公會頒佈之香港財務 報告準則編製,並已由本公司審核委員會(「審核委員會」)審閱。 ...
隆成金融(01225) - 2022 - 年度财报
2023-04-27 14:49
Financial Performance - Revenue for 2022 was HK$218.238 million, a slight increase from HK$215.287 million in 2021[6] - Pre-tax loss for 2022 was HK$345.563 million, representing 158.3% of revenue, a significant increase from 29.2% in 2021[6] - The company's consolidated revenue for the year ended December 31, 2022, was approximately HKD 218.2 million, an increase of 1.4% compared to the previous year, primarily driven by growth in medical products and plastic toys business[18] - The company reported a net loss of approximately HKD 367.6 million for the year ended December 31, 2022, compared to a net loss of HKD 65.9 million in the previous year, mainly due to impairment losses on receivables of approximately HKD 288.2 million[18] - The company's gross profit margin decreased by 2.0 percentage points to 66.6% for the year ended December 31, 2022, compared to 68.6% in the previous year[18] - The company's cash and cash equivalents increased by approximately HKD 25.2 million to HKD 175 million as of December 31, 2022, compared to HKD 149.8 million in the previous year[19] - The company's asset-liability ratio increased to 116.0% as of December 31, 2022, compared to 74.5% in the previous year[19] - The company's liquidity ratio decreased to 8.0 as of December 31, 2022, compared to 11.3 in the previous year[19] - The company's payable bonds amounted to approximately HKD 789.7 million as of December 31, 2022, compared to HKD 786.9 million in the previous year[19] - The company's distributable reserves at the end of the reporting period were HKD -98,639 thousand, compared to HKD -542,514 thousand in the previous year[172] - The company did not recommend the payment of a final dividend for the year ended December 31, 2022[168] - The company's property revaluation resulted in a gain of HKD 6,221,000, which was recorded in the property revaluation reserve as of December 31, 2022[169] - The company's top five customers accounted for approximately 36% of total sales, with the largest customer contributing about 14% of total sales[191] - The company's top five suppliers accounted for less than 24% of total purchases, with the largest supplier contributing about 9% of total purchases[191] - The company's property, plant, and equipment changes are detailed in Note 16 of the consolidated financial statements for the year ended December 31, 2022[170] - The company's share capital changes are detailed in Note 30 of the consolidated financial statements for the year ended December 31, 2022[171] - The consolidated financial statements for the year ended December 31, 2022, were prepared in accordance with Hong Kong Financial Reporting Standards and fairly present the company's financial position and performance[200] Business Segments - Medical product sales revenue increased by 22.0% to HK$85.5 million in 2022, accounting for 92.0% of the medical products and plastic toys business revenue[9] - Plastic toy sales revenue decreased by 40.1% to HK$7.4 million in 2022 due to intense market competition[9] - Securities brokerage and margin financing revenue decreased to HK$3.2 million in 2022 from HK$7.0 million in 2021, representing 1.5% of total group revenue[10] - The company's asset management business did not generate any revenue in 2022 due to weak market conditions and decreased investor enthusiasm[10] - The company operates in financial services, including securities brokerage, margin financing, and lending, as well as manufacturing and distributing children's plastic toys and medical products[92] Loans and Financing - Secured and unsecured loans as of December 31, 2022, were HK$112.1 million and HK$1,088.7 million, respectively[13] - The company plans to focus more on secured loans in the future when considering new loan applications[13] Corporate Governance - The Board of Directors consists of 3 executive directors and 3 independent non-executive directors as of the annual report date[42] - All independent non-executive directors have provided annual confirmation of their independence in accordance with listing rules[43] - The company has purchased appropriate insurance for directors and senior management against legal liabilities[40] - The Board is responsible for overall business development, strategy planning, major investments, and financial performance review[38] - Independent non-executive directors serve on Audit, Remuneration, and Nomination Committees[43] - Directors must retire by rotation at least once every three years according to the company's articles of association[45] - The Nomination Committee oversees board composition, appointment processes, and succession planning[45] - All directors must act in good faith and in the best interests of the company and its shareholders[39] - The company complies with the Corporate Governance Code as set out in Appendix 14 of the Listing Rules[37] - Directors are required to promptly disclose inside information unless it falls within the safe harbor provisions of the Securities and Futures Ordinance[40] - The Board of Directors held 5 meetings in 2022 to review and approve financial and operational performance, as well as overall strategy and policies[49] - Attendance records for Board meetings in 2022: Chen Junjie (2/5), He Guanli (5/5), Liang Jinbo (5/5), Yu Dazhi (5/5), Yang Haihui (3/5), Lin Quanzhi (5/5)[49] - The company has established a Board Diversity Policy to promote sustainable and balanced development, considering factors such as gender, age, cultural background, and professional experience[59] - The Nomination Committee is responsible for reviewing the Board's structure, size, and composition, and making recommendations for changes[60] - The company provides comprehensive induction materials and training for newly appointed directors to ensure they are fully informed of their duties and responsibilities[50] - The Board has established three committees: Nomination Committee, Remuneration Committee, and Audit Committee, each with specific written terms of reference[55] - The Nomination Committee consists of 5 members, with He Guanli as the chairperson, and is responsible for reviewing the Board's composition and making recommendations for appointments[56] - The company has adopted the Model Code for Securities Transactions as set out in Appendix 10 of the Listing Rules[51] - All directors confirmed compliance with the Model Code for Securities Transactions for the entire year of 2022[53] - The Board is responsible for making decisions on significant matters, including approving and monitoring policies, overall strategy, budgets, and major transactions[54] - The Remuneration Committee consists of five members, with the majority being independent non-executive directors, chaired by Mr. Yu Tat-chi[62] - The Remuneration Committee held one meeting during the year, with all members attending[64] - The Audit Committee includes three independent non-executive directors, chaired by Mr. Yu Tat-chi[67] - The Audit Committee held two meetings during the year, with all members attending[70] - The Board is responsible for maintaining adequate risk management and internal control systems, reviewed annually by the Audit Committee[74] - The company has implemented a whistleblowing policy allowing anonymous reporting of suspected misconduct to the Board or Audit Committee[76] - The company has a zero-tolerance anti-corruption policy and provided anti-corruption training averaging 3 hours per employee[76] - No legal cases related to corruption or serious violations of the Prevention of Bribery Ordinance were reported during the year[76] - The company's external auditor, Kaiyuan Xinde Certified Public Accountants Limited, was paid HKD 710,000 for audit services for the annual financial statements[80] - The audit committee recommended the reappointment of Kai Yuan Xinde CPA Limited as the company's auditor, and the auditor has expressed willingness to accept the reappointment[198] Shareholder Information - The company's Annual General Meeting (AGM) is scheduled to be held on June 27, 2023, with the notice to be sent at least 20 full business days prior[81] - Shareholders holding at least 10% of the company's paid-up share capital can request a special general meeting by submitting a written request to the board or company secretary[86] - The company's investor relations website, www.lerado.com, provides updates on business operations, financial data, and corporate governance practices[88] - Shareholders can submit inquiries to the board via mail or email at public@lerado.com.hk[85] - The company's investor relations department can be contacted at (852) 3700 9600 or via email at public@lerado.com.hk[89] - The company's major shareholder, Opus Platinum Growth Fund, held 18,000,000 ordinary shares, representing 7.82% of the issued share capital[185] - The company has maintained sufficient public shareholding throughout the year ended December 31, 2022[196] - The company has adopted a share option plan as an incentive for directors and eligible employees, with details provided in Note 32 of the consolidated financial statements for the year ended December 31, 2022[194] - The company did not engage in any purchases, sales, or redemptions of its listed securities during the year ended December 31, 2022[193] Environmental, Social, and Governance (ESG) - The company's ESG report for 2022 covers its sustainability performance from January 1, 2022, to December 31, 2022, focusing on key material issues[93] - Total greenhouse gas emissions in 2022 were 15.1 tons of CO2 equivalent, with an emission density of 3.0 tons of CO2 equivalent per employee[106] - Scope 2 emissions in 2022 were 14.9 tons of CO2 equivalent, a significant increase from 3.7 tons in 2021[107] - Scope 3 emissions in 2022 were 0.2 tons of CO2 equivalent, a decrease from 4.0 tons in 2021[107] - The company has not set direct greenhouse gas reduction targets but has established electricity consumption targets for operations[106] - The company encourages employees to use teleconferencing and public transportation to reduce emissions from business travel[107] - The company identified five key ESG issues as relevant and significant: employment, health and safety, development and training, anti-corruption, and resource use[101] - The company's environmental impact primarily stems from energy use in office operations, with a focus on energy efficiency and waste recycling[105] - The company conducts regular internal materiality assessments to determine the most important sustainability issues for the group[101] - The company has a dedicated ESG working group that reports to the board and implements policies and measures for sustainable development[99] - The company emphasizes transparency and accountability as key to building trust with stakeholders[98] - Total electricity consumption in 2022 was 21.0 MWh, with an intensity of 4.2 MWh per employee[112][113] - The company aims to reduce energy density by 15% by 2027, based on the 2022 benchmark of 4.2 MWh per employee[113][114] - Water consumption in 2022 was 0.9 cubic meters, with a density of 0.17 cubic meters per employee[117] - The company has implemented measures such as using LED lighting, adjusting air conditioning to 25°C, and promoting energy-efficient equipment[115] - The company has achieved its 2021 energy-saving target and continues to promote water-saving measures among employees[114][117] - The company has no significant water consumption related to operations, as water usage is primarily for drinking purposes[116] - The company has no significant packaging material consumption due to its business nature[118] - The company provides a total of 15 hours of training distributed across all employee categories, with an average of 3 hours per employee[135] - 60% of female employees and 40% of male employees received training, with 60% of senior management, 40% of middle management, and 20% of supervisors and general employees trained[136] - The company strictly adheres to laws and regulations regarding child labor and forced labor, employing only applicants aged 18 or above[137] - No major violations of labor standards, including the Hong Kong Employment Ordinance, were noted during the reporting period[138] - The company ensures compliance with the Securities and Futures Ordinance and requires all employees to follow the Securities Industry Operations and Compliance Manual[141] - No incidents of customer privacy violations or data loss were reported during the reporting period[142] - The company emphasizes business integrity and fair competition, requiring employees to adhere to the highest ethical standards and report potential conflicts of interest[143] - Different levels of service contracts require approval by authorized personnel, following the company's established policies[144] - Total greenhouse gas emissions increased to 15.1 tons of CO2 equivalent in 2022, up from 7.7 tons in 2021, with Scope 2 emissions rising significantly to 14.9 tons from 3.7 tons[150] - Energy consumption increased to 21.0 MWh in 2022, up from 5.3 MWh in 2021, with energy density per employee rising to 4.2 MWh from 1.1 MWh[150] - Water consumption decreased to 0.9 cubic meters in 2022, down from 1.2 cubic meters in 2021, with water density per employee dropping to 0.17 cubic meters from 0.24 cubic meters[150] - Employee turnover rate decreased to 20% in 2022, down from 120% in 2021, with male employee turnover dropping to 50% from 100%[155] - All employees received anti-corruption training, with an average of 3 hours per employee, covering senior management, middle management, supervisors, and other staff[146] - The company maintained a 100% employee training rate in both 2022 and 2021, with female employees accounting for 60% of trained staff in 2022, up from 40% in 2021[158] - Average training hours per employee increased to 3 hours in 2022, up from 2 hours in 2021, consistent across all employee categories and functions[161] - The company reported no legal cases related to corruption or significant non-compliance with the Prevention of Bribery Ordinance during the reporting period[147] - The company's community investment strategy includes regular reviews of environmental protection and social responsibility measures to ensure compliance with regulations[148] - The company's workforce remained stable at 5 employees in 2022, with a shift in gender composition to 3 female and 2 male employees, compared to 2 female and 3 male employees in 2021[152] - The company conducted one anti-corruption training session, totaling 3 hours, with 100% of directors and 60% of general employees participating[163] Miscellaneous - The company has no significant contingent liabilities as of December 31, 2022[27] - The company employs approximately 210 employees, with 180 based in China and the remaining in Hong Kong as of December 31, 2022[28] - The company has no significant investments exceeding 5% of its total assets as of December 31, 2022[20] - The company's office at 4/F, F&G, Kam Yat Building, 59-67 Bonham Strand West, Sheung Wan, Hong Kong, has a floor area of 1,000 square feet[94] - The company's ESG report is prepared in accordance with Appendix 27 of the Hong Kong Stock Exchange Listing Rules, focusing on mandatory key performance indicators[95] - No significant events occurred after the reporting period up to the date of the annual report[197]
隆成金融(01225) - 2022 - 年度业绩
2023-04-02 22:11
香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示,概不對因本公佈全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Lerado Financial Group Company Limited 隆 成 金 融 集 團 有 限 公 司 (於百慕達註冊成立之有限公司) (股份代號:1225) 截至二零二二年十二月三十一日止年度之 全年業績公佈 隆成金融集團有限公司(「本公司」)董事(「董事」)會(「董事會」)呈列本公司及其 附屬公司(統稱「本集團」)截至二零二二年十二月三十一日止年度之經審核綜合 業績連同比較數字,載列如下: 綜合損益及其他全面收益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 持續經營業務 收入 3 -商品及服務 94,112 84,266 -利息 124,126 131,021 ...
隆成金融(01225) - 2022 Q3 - 季度财报
2022-11-11 09:48
Loan Portfolio - As of December 31, 2021, the company had a total of HKD 303.3 million in secured loans and HKD 1,149.4 million in unsecured loans[5]. - The lending business had 163 borrowers as of December 31, 2021[4]. - The company has a total of 20 major borrowers with outstanding loans, with the highest individual loan amount being HKD 8,140,000[5]. - As of December 31, 2021, the total outstanding loans amounted to HKD 1,452,708,000, an increase from HKD 1,397,480,000 in 2020[10]. - Loans due within one year accounted for 38.2% of the total, increasing from 14.9% in the previous year[10]. - Loans due between 1 to 5 years represented 61.8% of the total, down from 82.0% in 2020[10]. - There were no loans due after 5 years as of December 31, 2021, compared to 3.1% in 2020[10]. Lending Strategy - The company plans to focus more on secured loans in future lending applications[5]. - The company has implemented a credit risk assessment process before granting loans, which includes evaluating the borrower's financial status and collateral value[7]. - The company regularly monitors loan repayment situations and takes action on overdue accounts, including legal proceedings if necessary[7]. - The company conducts background checks on corporate and individual clients as part of its due diligence process[8]. Compliance and Funding - The company has complied with the listing rules regarding loans to borrowers with outstanding loans as of December 31, 2021[9]. - The company has no agreements or arrangements with related parties concerning loans to borrowers with outstanding loans as of December 31, 2021[9]. - The company sources its lending funds from internal resources[5].
隆成金融(01225) - 2022 - 中期财报
2022-09-29 08:44
Financial Performance - Revenue for the six months ended June 30, 2022, was HKD 83,210,000, a decrease of 18.6% compared to HKD 102,104,000 in the same period of 2021[4] - The cost of goods sold increased to HKD 36,015,000, resulting in a gross profit of HKD 47,195,000, down from HKD 78,318,000 in the previous year[4] - The company reported a loss before tax of HKD 99,860,000, compared to a loss of HKD 2,406,000 in the same period last year, indicating a significant decline in performance[4] - Total comprehensive loss for the period was HKD 106,762,000, compared to HKD 7,076,000 in the previous year, reflecting a substantial increase in losses[6] - Basic and diluted loss per share from continuing and discontinued operations was HKD 43.74, compared to HKD 3.53 in the same period of 2021[7] - Total comprehensive income for the period was a loss of HKD 93,069,000, significantly higher than the loss of HKD 7,076,000 reported in the previous year[12] - The company reported a significant increase in administrative expenses to HKD 26,391,000 from HKD 34,867,000, impacting overall profitability[4] - The company reported a loss of approximately HKD 101,100,000 for the six months ended June 30, 2022, compared to a loss of HKD 8,400,000 in the previous year[73] Assets and Liabilities - Non-current assets decreased to HKD 99,052,000 from HKD 101,849,000 as of December 31, 2021[9] - Current assets decreased to HKD 1,874,984,000 from HKD 1,929,221,000, indicating a decline in liquidity[9] - Current liabilities increased to HKD 204,130,000 from HKD 170,946,000, suggesting a rise in short-term obligations[11] - Total equity decreased to HKD 962,608,000 from HKD 1,055,677,000, reflecting a decline in shareholder value[11] - The asset-liability ratio as of June 30, 2022, was approximately 82.7%, an increase from 74.5% in the previous year[74] Cash Flow - For the six months ended June 30, 2022, the company reported a net cash inflow from operating activities of HKD 3,816,000, compared to a net cash outflow of HKD 35,368,000 for the same period in 2021[14] - The company's cash and cash equivalents increased to HKD 157,303,000 as of June 30, 2022, compared to HKD 191,018,000 at the beginning of the year[14] - The company's cash and cash equivalents increased by approximately HKD 7,500,000 to about HKD 157,300,000 as of June 30, 2022, compared to HKD 149,800,000 as of December 31, 2021[74] Revenue Breakdown - Revenue from medical products increased to HKD 42,892,000 in 2022, up from HKD 23,248,000 in 2021, representing an increase of 84.5%[26] - Revenue from plastic toys decreased to HKD 2,708,000 in 2022, down from HKD 6,662,000 in 2021, a decline of 59.4%[26] - Interest income from loans and finance leases decreased to HKD 37,336,000 in 2022, down from HKD 62,709,000 in 2021, a decline of 40.4%[26] - The revenue from the securities brokerage and asset management business was approximately HKD 1,500,000, a decrease of about 82.8% compared to the previous year[67] Impairments and Losses - The company reported a fair value loss of HKD 38,914,000 on financial assets for the six months ended June 30, 2022, compared to a gain of HKD 5,625,000 in the previous year[36] - The group recorded a fair value loss of approximately HKD 38,900,000 on trading investments for the six months ended June 30, 2022, compared to a loss of HKD 5,600,000 in the same period of 2021[49] - The company experienced a significant increase in trade and other receivables impairment losses, amounting to HKD 52,579,000 for the six months ended June 30, 2022, compared to HKD 1,061,000 in the same period of 2021[36] Shareholder Information - The company did not recommend any interim dividend for the six months ended June 30, 2022, consistent with the previous year[37] - Major shareholder Opus Platinum Growth Fund held 18,000,000 shares, representing 7.82% of the issued share capital as of June 30, 2022[96] Management and Governance - The company has not adopted new or revised Hong Kong Financial Reporting Standards that are expected to have a significant impact on its financial performance[19] - The company has not appointed a chairman and CEO as of June 30, 2022, and the board is actively seeking suitable candidates to fill these vacancies[98] - The audit committee, composed of three independent non-executive directors, has reviewed the accounting principles and discussed matters related to audit, internal control, and financial reporting for the six months ending June 30, 2022[99] - All directors confirmed full compliance with the standard code of conduct for securities trading during the six months ending June 30, 2022[100] Employment and Operations - The company employed a total of 161 employees as of June 30, 2022, down from 210 in the previous year[84] - The company continues to focus on its core business segments, including medical products and securities brokerage services, while evaluating potential market expansion opportunities[22] - The management team will continue to assess foreign exchange risks without any current hedging policies in place[81]
隆成金融(01225) - 2021 - 年度财报
2022-04-29 13:16
Financial Performance - Total revenue for the year 2021 was HKD 215,287,000, a slight increase of 3.5% compared to HKD 207,831,000 in 2020[7] - The company reported a pre-tax loss of HKD 62,894,000, which is 29.2% of total revenue, compared to a loss of HKD 21,026,000 (10.1% of revenue) in 2020[7] - Interest income from lending activities amounted to approximately HKD 124,200,000, a decrease of HKD 11,100,000 from the previous year, representing 57.7% of total revenue[12] - Sales revenue from medical products increased by 62.5% to approximately HKD 70,100,000, accounting for 85.0% of the medical products and plastic toys segment[10] - Revenue from European customers in the medical products and plastic toys segment rose by 58.0% to approximately HKD 55,800,000, representing 67.6% of the segment's total revenue[10] - The group reported a loss of approximately HKD 65.9 million for the year, compared to a loss of HKD 14 million in 2020, primarily due to an increase in impairment losses[18] - The total comprehensive loss for the year was HKD 58,820,000, a significant decrease from a comprehensive income of HKD 6,314,000 in the previous year[140] - The company reported a loss from continuing operations of HKD 62,938,000, compared to a loss of HKD 12,270,000 in 2020[140] Assets and Liabilities - The total assets of the company decreased to HKD 2,031,070,000 from HKD 2,113,199,000 in 2020[7] - The company's total assets decreased to HKD 1,860,124,000 from HKD 1,911,429,000 in 2020[146] - The company's equity decreased to HKD 1,055,677,000 from HKD 1,114,497,000 in 2020[146] - The company’s debt ratio increased to 74.5% in 2021 from 73.3% in 2020, indicating a higher level of leverage[7] - The group’s total liabilities to equity ratio was approximately 74.5% as of December 31, 2021, compared to 73.3% in the previous year[19] Cash Flow and Investments - Cash and cash equivalents decreased by approximately HKD 80.5 million to about HKD 149.8 million as of December 31, 2021, compared to HKD 230.2 million as of December 31, 2020[19] - The company experienced a cash outflow from operating activities of HKD 77,906,000 in 2021, compared to HKD 46,773,000 in 2020, representing an increase in cash outflow of approximately 66.5%[152] - The company recorded a net cash inflow from investing activities of HKD 8,051,000 in 2021, compared to a net cash outflow of HKD 57,000 in 2020, indicating a positive shift in investment cash flow[153] Inventory and Receivables - The average inventory turnover ratio increased to 114 days in 2021 from 107 days in 2020[7] - The company reported a significant increase in inventory to HKD 28,245,000 from HKD 13,807,000 in the previous year[144] - Total receivables amounted to approximately HKD 1,526,149,000 with cumulative impairment provisions of about HKD 91,473,000[128] - Total trade receivables as of December 31, 2021, were approximately HKD 201,963,000 with cumulative impairment provisions of about HKD 85,049,000[128] Corporate Governance - The board consists of three executive directors and three independent non-executive directors, ensuring compliance with listing rules[41] - The company has maintained adherence to the corporate governance code as per the listing rules throughout the fiscal year ending December 31, 2021[36] - The company has established committees for audit, remuneration, and nomination, enhancing governance and oversight[42] - The board is responsible for overall business development and shareholder value enhancement, including strategy formulation and financial performance review[37] - The company has a policy for the appointment and re-election of directors every three years, ensuring governance transparency[44] Risk Management and Internal Controls - The board is responsible for maintaining adequate risk management and internal control systems to protect shareholder investments and company assets[72] - The company has engaged an external professional firm to conduct internal audit functions, reviewing operational controls and risk management[73] - The audit committee is tasked with reviewing and monitoring the effectiveness of the external auditor's independence and audit procedures[65] Shareholder Communication - The company emphasizes the importance of effective communication with shareholders to enhance investor relations and transparency[77] - The company has a formal process for shareholders to raise inquiries and concerns to the board[80] - The annual general meeting is scheduled for June 28, 2022, providing a platform for direct communication between the board and shareholders[77] Compliance and Regulatory Matters - The company has established a governance policy to ensure compliance with legal and regulatory requirements[69] - The independent auditor has expressed an unqualified opinion on the consolidated financial statements for the year ending December 31, 2021[123] - The company has no significant contracts in which directors have a direct or indirect interest for the year ending December 31, 2021[111] Future Outlook - The company plans to expand its asset management business by launching various funds to attract new investors, although no revenue was generated from this segment in 2021[11] - The group expects that the application of all new and revised Hong Kong Financial Reporting Standards will not have a significant impact on the consolidated financial statements in the foreseeable future[160]
隆成金融(01225) - 2021 - 中期财报
2021-09-29 08:41
中期報告 2021 (於百慕達註冊成立之有限公司) 中期業績 隆成金融集團有限公司(「本公司」)董事(「董事」)會(「董事會」)呈列本公司及 其附屬公司(統稱「本集團」)截至二零二一年六月三十日止六個月之未經審核綜 合業績連同比較數字及經選擇說明附註,此乃根據香港會計師公會頒佈之香港財 務報告準則編製,並已由本公司審核委員會(「審核委員會」)審閱。 簡明綜合損益及其他全面收益表 截至二零二一年六月三十日止六個月 | | | 截至六月三十日止六個月 | | | --- | --- | --- | --- | | | 附註 | 二零二一年 | 二零二零年 | | | | 千港元 | 千港元 | | | | (未經審核) | (未經審核) | | | | | (經重列) | | 持續經營業務: | | | | | 收入 | | 102,104 | 96,352 | | 出售透過損益賬按公平值處理 | | | | | (「透過損益賬按公平值處理」))之 | | | | | 金融資產之所得款項總額 | | 5,911 | 783 | | | | 108,015 | 97,135 | | 收入 | 3 | 102,104 ...
隆成金融(01225) - 2020 - 年度财报
2021-04-29 09:05
(於百慕達註冊成立之有限公司) 年報 目錄 余達志先生 楊海琿先生 林全智先生 目錄 公司資料 執行董事 審核委員會 余達志先生 (主席) 林全智先生 楊海琿先生 薪酬委員會 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 3 | | 管理層討論與分析 | 4 | | 董事簡介 | 8 | | 企業管治報告 | 10 | | 董事報告書 | 22 | | 獨立核數師報告書 | 28 | | 綜合損益及其他全面收益表 | 33 | | 綜合財務狀況表 | 35 | | 綜合權益變動表 | 37 | | 綜合現金流動表 | 38 | | 綜合財務報表附註 | 40 | | 財務概要 | 136 | 1 隆成金融集團有限公司 陳俊傑先生 梁錦波先生 何觀禮女士 獨立非執行董事 余達志先生 (主席) 梁錦波先生 何觀禮女士 林全智先生 楊海琿先生 提名委員會 何觀禮女士 (主席) 陳俊傑先生 林全智先生 余達志先生 楊海琿先生 公司秘書 文潤華先生 註冊辦事處 Clarendon House 2 Church Street Hamilton HM11 Bermuda 主要營業地點 香港上環 皇 ...